BeiGene, Ltd. (BGNE)

Market Cap	16.92B
Revenue (ttm)	2.76B
Net Income (ttm)	-784.43M
Shares Out	104.07M
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100,268
Open	163.82
Previous Close	163.27
Day's Range	161.70 - 165.50
52-Week Range	126.97 - 225.23
Beta	0.59
Analysts	Strong Buy
Price Target	254.85 (+56.79%)
Earnings Date	Aug 9, 2024

About BGNE

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 10,600
• Stock Exchange: NASDAQ
• Ticker Symbol: BGNE

Financial Performance

In 2023, BeiGene's revenue was $2.46 billion, an increase of 73.65% compared to the previous year's $1.42 billion. Losses were -$881.71 million, -56.00% less than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for BGNE stock is "Strong Buy." The 12-month stock price forecast is $254.85, which is an increase of 56.79% from the latest price.

Price Target

$254.85

(56.79% upside)

Analyst Consensus: Strong Buy